Key Points Pevonedistat targets the NFκB pathway to inhibit growth of MPN and sAML cells. Pevonedistat reduces disease burden in MPN mouse models. Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition Abstract Targeted inhibitors of JAK2 (eg ruxolitinib) often provide symptomatic relief for myeloproliferative neoplasm (MPN) patients, but the malignant clone […]
New Horizons in MPN Treatment, A Review of Therapeutic Options
Abstract Philadelphia-negative myeloproliferative neoplasms (MPN) are aggressive diseases characterized by clonal proliferation of myeloid stem cells. The clonal process leads to excessive red cells production, platelets production, and bone marrow fibrosis. According to the phenotype, MPN can be classified as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). MPN patients have shortened survival […]
Myelofibrosis, New Markers of Disease Progression
Simple Summary Disease progression and prognosis in PMF are usually associated with worsening of anemia, increase of circulating blasts, and, more recently, with the presence, in addition to the “classical” driver mutations, of JAK2, MPL, and CALR genes, as well as of cytogenetic and molecular abnormalities that have been incorporated into new genetically based prognostic scoring systems. We have […]
MPN Clinical Trials 2021 Update
Patients are Asking – MPN Expert Dr. Andrew Kuykendall Episode 2 of 3 Update on MPN Clinical Trials in 2021. The PDUFA date is the end of the review period, where the FDA has to make a decision or respond to a New Drug Application (NDA) or a Biologics License Application (BLA). Ropeginterferon and Pacritinib […]
September is Blood Cancer Awareness Month for MPNs
by Lou Ann Donovan and David Wallace National Blood Cancer Awareness Month: Spotlight on Myeloproliferative Neoplasms September marks National Blood Cancer Awareness Month, an annual event established by Congress in 2010 to shed light on various blood diseases, including the lesser-known chronic blood cancers called Myeloproliferative Neoplasms (MPNs). The statistics are sobering: every three minutes, […]
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 35
- Next Page »
